Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pomalidomide Celgene

- PMLiVE

Ten new medicines recommended in Europe

Includes double approvals for rare disease specialist Alexion and Novartis

Roche Basel Switzerland

Roche maintains dominance as leading cancer drugmaker

But the firm’s growth is stalling as pricing pressures hit sales

- PMLiVE

Celgene’s psoriasis pill gives ‘no added benefit’ to patients

Germany’s cost assessor IQWiG says Otezla is not value for money

- PMLiVE

AbbVie remains top of immunology sales

But the threat of biosimilars once again threatens to shake up the leader board

- PMLiVE

Michael Zaiac moves from GSK to Celgene

He takes up the role of VP, medical affairs, haematology-oncology EMEA

Celgene building

Celgene to acquire biotech firm Quanticel Pharmaceuticals

Firm hopes to expand its pipeline of life-enhancing products for cancer patients

Celgene building

Celgene sets up stem cell deal with Mesoblast

Oncology drug specialist hoping to tap into possible treatments for Crohn's and cancer

- PMLiVE

Celgene name Gerald F. Masoudi as executive VP

Will take up the role of executive VP, general counsel and corporate secretary

- PMLiVE

Amgen gets quick US review for Kyprolis

To be considered as a second-line therapy for multiple myeloma

- PMLiVE

Final NICE ‘no’ for Celgene’s Imnovid

England’s pricing watchdog says multiple myeloma drug is just too expensive for the NHS

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Amgen hoping to topple Takeda’s $2bn a year drug

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links